Kornimate/medical-research-clean huggingface dataset:
the effect of whey protein and its hydrolysate on pre- and post-fixed meal glycemia and insulin in young adults

Conditions: Diabetes Prevention; Obesity Prevention

Summary: the purpose of this study is to describe relationships among whey protein and its hydrolysate when consumed before a meal on pre- and post-fixed meal satiety, blood glucose and insulin in healthy young adults.

a randomized, cross-over design study was conducted. whey protein preloads (5-40 g) and hydrolysate whey protein (10 g) were provided in 300 ml water. at 30 min following consumption, subjects were fed a preset pizza meal (12 kcal/kg, experiment 2). satiety, insulin and blood glucose were measured at baseline and selected intervals pre- and post-meal.

Eligibility criteria:
inclusion criteria: * normal body weight exclusion criteria: * breakfast skippers * smokers * dieters or individuals with diabetes (fasting blood glucose ≥ 7.0 mmol/l) or other metabolic diseases

Keywords: whey protein hydrolysate whey protein blood glucose insulin
dose-effect relationship between micrornas in peripheral blood and radiation injury

Conditions: Radiation Injuries, Experimental

Summary: rapid and accurate assessment of radiation injury dose is the key to success in early treatment and an urgent issue to be solved in clinical medicine.researches showed that the expression of the micrornas in human peripheral blood had much correlation with radiation injury resulted from different dosages of radiation.in this study,acute leukemic patients who will be pretreated by whole-body radiation are taked as the object of study,and biochip technology are adopted to detect the expression levels of the micrornas in subject peripheral blood before-and-after radiation,and different expression is tested and bioinformatics prediction,to evaluate the correlation between radiation injury dose and expression levels of the micrornas in human peripheral blood.


Eligibility criteria:
inclusion criteria: * subjects who suffer from acute leukemic subjects who accept chemotherapy within one month and will be pretreated by whole-body irradiation peripheral blood cells of subjects are approximate to those of healthy person aged between 18 and 50 years old subjects who are competent to give written informed consent subjects without other systemic diseases exclusion criteria: * subjects who suffer from serious other systemic diseases subjects who are unwilling or unable to cooperate with this clinical study other serious cases that probably hinder this clinical study

Keywords: radiation injuries microrna
a follow-up study to wv19432, to evaluate long term post-treatment effects of pegasys (peginterferon alfa-2a(40kd))in patients with hbeag positive chronic hepatitis b

Conditions: Hepatitis B, Chronic

Summary: this study is a long-term post-treatment follow-up to study wv19432, which evaluated the efficacy and safety of pegasys in patients with hbeag positive chronic hepatitis b (chb).patients who received treatment with pegasys, and completed follow-up, are eligible to enter this post-treatment follow-up study. the anticipated time on study was 5 years, and the target sample size is 100-500 individuals.


Eligibility criteria:
inclusion criteria: * informed consent for study wv19432 * patients who have completed treatment and follow-up on study wv19432 exclusion criteria: * as for study wv19432
a study of glucose control in participants with type 1 and type 2 diabetes

Conditions: Type 1 Diabetes; Type 2 Diabetes

Summary: the main purpose of this study is to determine whether combining meal, glucose and insulin data in a web-based system will improve management of type 1 (t1d) and type 2 diabetes (t2d). no study drug will be given. the study will last about 18 weeks.


Eligibility criteria:
inclusion criteria: * individuals with type 1 or type 2 diabetes for \>3 years by clinical diagnosis who use basal insulin, in addition to at least one injection of meal time insulin per day * insulin pen use for at least 3 months * current use of or willingness to use dexcom g6 at least 6 out of 7 days per week * a1c 6.5-9.5% exclusion criteria: * currently using any form of insulin pump, including hybrid closed-loop system (e.g., medtronic 670g) * individuals requiring single insulin boluses of \>40 units * individuals planning to follow a specific diet plan for weight loss * inability to consume regular, consistent meals * individuals who have had severe hypoglycemia with seizure or coma within the past 6 months * individuals who have been hospitalized for diabetic ketoacidosis (dka) within the past 6 months

Keywords: t1d t2d
variability of whole blood clotting time measurements in ex vivo human blood samples spiked with anticoagulants

Conditions: Healthy

Summary: the study will assess the distribution and variability of whole blood clotting time (wbct) measurement in human blood collected from healthy volunteers that is untreated and spiked with predetermined concentrations of edoxaban or enoxaparin.

twelve healthy volunteers aged 18 to 65 years (6 subjects per spiking anticoagulant) will be enrolled. a total of 8 blood samples (12 ml/sample) will be collected by direct venipuncture. the samples from will be spiked with predetermined concentrations of edoxaban or enoxaparin (baseline, saline control and 6 specified concentrations of anticoagulant). each blood sample will be tested for whole blood clotting time (wbct), point of care activated partial thromboplastin time (aptt) and prothrombin time (pt).

Eligibility criteria:
inclusion criteria: 1. signed and dated informed consent form 2. healthy male and female subjects aged 18 to 65 years (inclusive) with suitable veins for venipuncture - exclusion criteria: 1. subjects who cannot communicate reliably with the investigator 2. history of major bleeding or major trauma within the 6 months prior to signing informed consent 3. propensity to bleeding (i.e. due to recent trauma, surgery, peptic ulcer, gastrointestinal bleeding or hemorrhoids) 4. significant infection or known inflammatory process in the 2 weeks prior to screening 5. active smoker or current use of any tobacco products or use within 3 months prior to signing informed consent 6. treatment with any investigation product or therapy within 30 days prior to screening 7. received non-steroidal antiinflammatory drugs or medications (including anticoagulants or aspirin) with a direct effect on hemostasis within 7 days of blood sampling 8. unwilling to comply with the procedures in the protocol 9. currently enrolled in any other study -

Keywords: whole blood clotting time
confocal laser endomicroscopy vs conventional histology for the identification of intestinal metaplasia

Conditions: Barrett's Esophagus

Summary: real-time diagnosis of barrett's esophagus: comparing confocal laser endomicroscopy with conventional histology for the identification of specialized intestinal metaplasia

the incidence of esophageal adenocarcinoma has risen over 800% over the past several decades and is associated with a high mortality rate. barrett's esophagus (be) has been identified as the number one risk factor for the development of esophageal adenocarcinoma. gastroesophageal reflux disease (gerd) has been identified as the major risk factor for development of be. current guidelines for be diagnosis and surveillance, according to the seattle protocol, include four-quadrant random biopsies at 2-cm intervals (1-cm intervals if suspected high grade intraepithelial neoplasia). this random biopsy protocol can be time-consuming, expensive, and prone to sampling error, as very little of the esophageal surface area is actually sampled. probe-based confocal laser endomicroscopy (pcle) generates optical biopsies, providing physicians with microscopic images of tissue instantaneously and in a minimally invasive manner. comparing pcle with conventional histology for the identification of specialized intestinal metaplasia has the potential to result in a new standard of care for the diagnosis of be. the aim of this study is to compare pcle to traditional tissue biopsies for the diagnosis of be. a patient with gerd will be scheduled for upper endoscopy as part of routine evaluation. routine endoscopy will be performed, including white light and narrow band imaging photo documentation. probe-based confocal laser endomicroscopy will be performed at the gastroesophageal junction. biopsies of columnar lined esophagus will then be taken in four quadrants starting at the squamocolumnar junction and proceeding in 1 cm segments to the gastroesophageal junction. optical biopsy images will be reviewed immediately following endoscopy by endoscopist and later reviewed by blinded independent reviewer. pathology specimens will be reviewed by a pathologist. the results of the optical biopsies obtained with probe-based confocal laser endomicroscopy will be compared with the pathology results.

Eligibility criteria:
inclusion criteria: * age \>18; clinical diagnosis of gerd; undergoing upper endoscopy for reflux evaluation exclusion criteria: * age \<18, contraindication to receiving fluorescein, inability to provide informed consent, history of esophageal ablation

Keywords: probe-based confocal laser endomicroscopy
a research study comparing rybelsus® to other blood sugar lowering tablets in people living in america with type 2 diabetes (realyse)

Conditions: Diabetes Mellitus, Type 2

Summary: this study is comparing the medicine rybelsus® to other medicines in people with type 2 diabetes who need extra treatment. all medicines used in this study are tablets which lower blood sugar in people with type 2 diabetes. the purpose of the study is to see how well rybelsus® is at lowering blood sugar compared to other tablets when used in addition to metformin. participants doctor will give participants either rybelsus® or any other blood sugar lowering tablets - which treatment participants get is decided by chance. the doctor treating participants diabetes will give participants a prescription for the medicine and tell how to take it. the study will last for about 1 year. participants will have 2 planned visits with their doctor which are part of the usual routine diabetes management: the first visit is when participants are included in the study, the second visit is a 1-year follow-up visit. in addition, the study personnel will contact participants up to 3 times during this period and to follow-up on information from participant doctors visits. participant will be asked to respond 3 times to 4 questionnaires via their personal smartphone or tablet or paper if participant do not have access to one during the study. all clinic visits are part of the usual routine diabetes management and are covered by participants health insurance plan. the study team will collect information from these visits recorded in the medical chart. women cannot take part if pregnant, breast-feeding or plan to become pregnant during the study period.


Eligibility criteria:
key inclusion criteria * treatment with metformin as monotherapy prior to eligibility assessment that has failed to result in adequate glycemic control at the discretion of the investigator or treatment provider. however, prior short-term treatment with an oral glucose lowering agent or insulin for up to 14 consecutive days in addition to metformin is allowed if discontinued prior to screening. * current member of a health plan which includes pharmacy benefits. * hba1c greater than or equal to 7% within last 90 days prior to the day of screening or to be taken before randomization. * further intensification with an additional glucose-lowering oral agent including oral semaglutide is indicated according to approved prescribing information to achieve glycemic target at the discretion of the treatment provider. key exclusion criteria: * female who is pregnant, breast-feeding or intends to become pregnant or is of child-bearing potential and not using contraception. * any disorder which in the investigator's or treatment provider's opinion might jeopardize patient's safety.
oxytocin i.m./i.v. versus carbetocin i.v. in elective cesarean sections

Conditions: Postpartum Hemorrhage

Summary: objective is to proof non-inferiority of intramyometrial and intravenous oxytocin application compared to intravenous carbetocin for prevention of postpartum hemorrhage in planned, uncomplicated cesarean deliveries.


Eligibility criteria:
inclusion criteria: * elective cesarean section * present informed consent * completed 36 weeks of gestation exclusion criteria: * need for intubation (carbetocin is only licensed for epidural or spinal anesthesia) * multiple fetus pregnancy * known coagulopathy * placenta praevia * morbidly adherent placenta * placental abruption * thrombocyte dysfunction * hellp-syndrome * preeclampsia * history of uterine atony
a pilot trial of the non-invasive h.g.r glucometer

Conditions: Type 2 Diabetes

Summary: a pilot study evaluating the accuracy of a non-invasive glucose monitor (gwave) with venous glucose measured by core laboratory during a glucose tolerance test (gtt) in patients with type 2 diabetes. the study is conducted on 5 subjects undergoing a 75gr gtt, with blood glucose measured at baseline and at 8 time points up to 180 minutes post glucose ingestion both by gwave non-invasive glucometer and by core lab glucose measurement.


Eligibility criteria:
inclusion criteria: 1. informed consent obtained before any study-related activities. study-related activities are any procedures that are carried out as part of the study, including activities to determine suitability for the study. 2. male or female. 3. age above or equal to 18 years at the time of signing informed consent. 4. diagnosed with type 2 diabetes mellitus ≥ 180 days before screening. 5. hba1c of 6.0-8.0% . exclusion criteria: 1. participants under the age of 18 years 2. pregnant women or patients with normal blood glucose.
pre-habilitation interventions to empower patients with chronic pain

Conditions: Chronic Non-Cancer Pain

Summary: the development of alternative methods to address simple clinical needs and easy interventions of self-application are desired in the pre-habilitation period (waiting list). to our knowledge that are very few studies regarding interventions for patients in waiting list for specialized treatment of chronic non-cancer pain (cncp) and they do not include cognitive-behavioural programs. this project is based on the hypothesis that educational and cognitive-behavioural interventions help to reduce deleterious effects of pain on some areas of patient's life. therefore, the goal is to test two different interventions to help patients to self-manage their pain and avoid worsening in the pre-clinical period.

it is a randomized controlled trial for application and assessment of two interventions: an educational video-based pain program (vp) and empowered relief program (er). the primary purpose of our study is to investigate the effect of er and vp on the pain catastrophizing score in people with cncp who are waiting for multidisciplinary pain treatment. the secondary aim is to analyse the effects on other patient reported outcomes such as pain intensity, pain interference in daily activities, pain catastrophizing, pain acceptance, quality of life, mood, perceived change on over-all pain status, as well as consumption of pain medicine and usage of healthcare services. the effects of the two interventions will be compared with each other and a control group.

Eligibility criteria:
inclusion criteria: * first appointment date at the multidisciplinary pain centre scheduled at least three months after the invitation to participate in this study * at least 18 years old * fluent in the danish language * access to internet * willing and available to participate in the study exclusion criteria: * history of cognitive dysfunction that interfere with understanding of the educational program and answering the questionnaires * epilepsy * current history of severe depression * current use of private pain services

Keywords: chronic non-cancer pain cognitive-behavioral program waiting list pain catastrophizing patient reported outcomes
the clever study - coreg and left ventricular mass regression

Conditions: Hypertrophy, Left Ventricular

Summary: this study is designed to compare the effects of coreg mr (carvedilol modified release formulation) to atenolol on indices of left ventricular dimensions when added to standardized angiotensin converting enzyme (ace) inhibition, and to the effect of ace inhibition alone. subjects with lvh (left ventricular hypertrophy) and hypertension will be studied. the primary endpoint will be the change in left ventricular mass index (lvmi) characterized by magnetic resonance imaging (mri) following 12 months of treatment. secondary endpoints include the change in lv (left ventricular) mass, lv wall thickness, diastolic left ventricular filling parameters, and left ventricular ejection fraction by echocardiographic methods at treatment month 12. composite outcomes and individual event data will also be evaluated by treatment group.

a randomized, double-blind, multi-center study comparing the effects of carvedilol modified release formulation (coreg mr) and atenolol in combination with and compared to an angiotensin converting enzyme inhibitor (lisinopril) on left ventricular mass regression in hypertensive patients with left ventricular hypertrophy (lvh).

Eligibility criteria:
inclusion criteria: * stage 1 or stage 2 hypertension. * left ventricular hypertrophy. exclusion criteria: * in atrial fibrillation. * takes beta-blocker for mi (myocardial infarction) or arrhythmia. * has uncontrolled diabetes, uncontrollable or symptomatic arrhythmias, unstable angina, second or third degree heart block, history of mi, copd (chronic obstructive pulmonary disease), liver or kidney disease. * uses beta-2-agonists. * unable to undergo mri (magnetic resonance imaging). * females of childbearing potential.

Keywords: left ventricular hypertrophy (lvh) echocardiogram left ventricular mass regression cardiac mri left ventricular mass index (lvmi)hypertension
the effect of the menstrual cycle on immune cell activity and recovery after resistance exercise

Conditions: Healthy Women; Menstruation; Resistance Exercise

Summary: the goal of this observational study is to learn how the menstrual cycle affects immune cell activation, recruitment, and recovery responses after resistance exercise in healthy, resistance-trained women aged 18-40. the main questions it aims to answer are: does the menstrual cycle influence neutrophil recruitment and adhesion after resistance exercise? does the menstrual cycle affect markers of muscle damage and functional recovery? researchers will compare three menstrual phases (early follicular, late follicular, and mid-luteal) to see if immune responses and recovery outcomes differ across these phases. participants will: complete resistance exercise protocols across three different menstrual cycle phases. provide blood samples to assess immune cell activation and muscle damage markers. track sleep, mood, and recovery with questionnaires and wear an accelerometer.


Eligibility criteria:
inclusion criteria: * women between the ages of 18 and 40. * must weigh at least 110 pounds. * healthy as determined by medical history, physical activity readiness, and menstrual cycle questionnaires. * actively resistance training for at least 6 months (minimum of 3 resistance training sessions per week, with at least one lower body session). * pre-menopausal and have a regular menstrual cycle (eumenorrheic), with a clear start of menses (early follicular phase). * not currently pregnant or planning to become pregnant during the study. * have not used hormonal birth control or intrauterine devices in the past 3 months (or three full menstrual cycles). * able to recall approximate start dates of their last 6 menstrual cycles. * willing to follow study instructions, including avoiding exercise, alcohol, and caffeine before testing visits. * free from previous or current lower body injuries that could limit performance. * not regularly taking any medications that could interfere with the study. * determined to have a high likelihood of successful blood draws by a certified phlebotomist. exclusion criteria: * do not give consent to participate. * have been determined unfit to participate based on medical or activity history (using health questionnaires). * currently take prescription or over-the-counter medication that could affect the study results. * have a chronic illness requiring medical care. * not currently resistance-trained (don't meet the exercise requirement). * pregnant or planning to become pregnant during the study. * do not have regular periods or have been diagnosed as amenorrhoeic (absence of menstruation). * currently taking any performance-enhancing drugs. * currently using hormonal birth control or intrauterine devices (iuds), or have used them in the past three months (or three full menstrual cycles). * determined unlikely to have a successful blood draw by a trained phlebotomist. * weigh less than 110 pounds.
clinical research on shenfu injection in septic patients

Conditions: Sepsis

Summary: sepsis, characterized by organ dysfunction caused by infection, exhibits increasing incidence and mortality rates, posing a significant challenge to intensive care units. early-stage sepsis involves hemodynamic disturbances, and severe and complex microcirculatory impairments can result in tissue hypoxia and accelerate organ dysfunction. modern medical research has indicated that the effective and rapid restoration of microcirculatory function, along with the correction of microcirculatory disorders, is a crucial aspect in the treatment of sepsis. current guidelines recommend the use of vasoactive drugs to address hemodynamic disturbances, but their administration may further damage the microcirculation. additionally, in patients with severe sepsis, there often exists a disparity between macrocirculatory and microcirculatory hemodynamics, and conventional clinical indicators fail to directly reflect the level of microcirculatory perfusion. chinese guidelines have incorporated the use of traditional chinese medicine (tcm) in the diagnosis and treatment of sepsis, offering a new therapeutic approach to ameliorate microcirculatory impairments. this study aims to include patients with sepsis and administer shenfu injection via intravenous therapy. tongue microcirculation assessment will be employed to evaluate changes in microvascular health scores, while transcutaneous oxygen and carbon dioxide pressure alterations, as well as serum lactate level variations, will be monitored to ascertain the effects of shenfu injection on improving early-stage microcirculatory impairments and microvascular leakage in sepsis patients. this research will clarify the clinical efficacy of shenfu injection in sepsis patients with microcirculatory impairments, provide evidence-based medicine and clinical evidence for tcm treatment of sepsis, and offer a solid foundation for refining sepsis treatment strategies with distinct chinese characteristics.


Eligibility criteria:
inclusion criteria: * age ≥ 18 years; * signed informed consent form; * meets sepsis 3.0 diagnostic criteria; exclusion criteria: * age \< 18 years; * known pregnancy; * inability to accept and complete signed informed consent within 24 hours of diagnosis of sepsis; * status of tracheal intubation; * oral mucosal inflammation or damage; * patients with contraindications to transcutaneous oxygen partial pressure testing such as severe edema and burns; * concurrent participation in other treatment studies.

Keywords: sepsis microcirculation shenfu injection